The UK and US have forged a landmark trade agreement that will guarantee zero levies on UK pharmaceutical exports going into the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has committed to increase spending on medicines through the National Health Service (NHS). This move secures that tariffs on these key goods will remain at zero for a timeframe of 36 months.
This development follows recent warnings to significantly raise duties on branded pharmaceutical imports, with increases mentioned reaching one hundred percent.
"This agreement with the UK strengthens the worldwide climate for new treatments and introduces much-needed fairness to American-British drug exports," a release noted.
Economic Importance
Medicines are one of the Britain's largest exports to the United States, which is easily the largest market for large UK drugmakers.
Statistics reveal that in the 12 months prior to September, the UK shipped medicines worth £11.1bn to the US. This figure accounted for a significant portion of all goods exports in that timeframe.
"This agreement secures jobs, stimulates funding and sets the stage for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary stated.
Specific British Pledges
The pact involves several notable commitments from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it judges new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a target to double total NHS spending on treatments from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at 15%. In the past, repayments topped 20%.
Broader Context
The pact takes place against a ongoing row between the pharmaceutical industry and the ministers over drug pricing and NHS adoption.
This friction were intensified by claims that US patients were paying significantly more for the equivalent treatments than people in the UK and Europe.
Recently, several major manufacturing plans in the UK have been delayed or abandoned, while major funding commitments have been announced toward projects in the United States.
A senior figure publicly accepted that the NHS must increase expenditure on medicines, noting that its spending on drugs had shrunk as a percentage of its resources over the past decade.
